[
    [
        {
            "time": "",
            "original_text": "毛利90%，稀缺性疫苗龙头即将上市！“激素茅”将迎来一次市值暴涨的机会？",
            "features": {
                "keywords": [
                    "毛利",
                    "90%",
                    "稀缺性",
                    "疫苗",
                    "龙头",
                    "上市",
                    "市值",
                    "暴涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物技术"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "毛利90%，稀缺性疫苗龙头即将上市！“激素茅”将迎来一次市值暴涨的机会？",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "新冠疫苗接种稳步推进 这些业绩预增股可提前布局丨牛熊眼",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "接种",
                    "稳步推进",
                    "业绩预增",
                    "布局"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新冠疫苗接种稳步推进 这些业绩预增股可提前布局丨牛熊眼",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "\"千亿大白马\"长春高新分拆上市再进一步！疫苗子公司百克生物发招股说明书！",
            "features": {
                "keywords": [
                    "千亿大白马",
                    "长春高新",
                    "分拆上市",
                    "疫苗",
                    "子公司",
                    "百克生物",
                    "招股说明书"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "\"千亿大白马\"长春高新分拆上市再进一步！疫苗子公司百克生物发招股说明书！",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]